Journal article icon

Journal article

Comparison between germline and somatic loss-of-function RNF43 mutations reveals different genotype-phenotype associations and provides insights into the genetic mechanisms of colorectal tumourigenesis

Abstract:
Background: Germline RNF43 mutations cause a dominantly inherited syndrome of colorectal cancer (CRC) and serrated polyps. However, these data originate from highly selected families. Objective: We assessed germline RNF43 variants in patients more representative of the general population and compared these with somatic RNF43mutations in CRCs. Design: We studied 49 823 CRC and/or polyp cases from the CORGI study, 100 000 Genomes (100kGP) and UK Biobank (UKB), alongside 165 250 controls. Somatic mutations were analysed in 2722 CRCs. Results: Consistent with the literature, a germline loss-of-function RNF43 variant (p.Thr158ProfsTer6) was found in a multigenerational CORGI family with early-onset CRC and serrated and/or filiform polyps. However, while 23 CRC/polyp cases and 47 controls from 100kGP or UKB had germline RNF43 mutations, cases often lacked multiple polyps or a notable family history. Sometimes, CRCs developed independently of the germline RNF43 mutation. In case-control analyses, germline RNF43 variants were associated with CRC risk (OR=2.696, p=0.010), but penetrance was much greater for germline mutations in the N-terminal half of the gene. Germline C-terminal mutations conferred no increased CRC risk. However, somatic C-terminal mutations were pathogenic, perhaps because their relatively weak effects are supplemented by accompanying mutations in Wnt genes, including ZNRF3 and a new driver, SFRP4. Conclusion: RNF43 is a CRC predisposition gene, but risks are moderate, the reported polyposis phenotype is often absent and molecular phenocopies can occur. N-terminal germline RNF43 variants confer higher risk, although weak effects of C-terminal variants cannot be excluded. Genetic testing and patient management should incorporate these factors.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1136/gutjnl-2025-337030

Authors

More by this author
Role:
Author
ORCID:
0000-0002-9670-2263
More by this author
Institution:
University of Oxford
Role:
Author
More by this author
Institution:
University of Oxford
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Sub department:
Oncology
Role:
Author


More from this funder
Funder identifier:
https://ror.org/029chgv08
More from this funder
Funder identifier:
https://ror.org/03ngjs524
More from this funder
Funder identifier:
https://ror.org/054225q67


Publisher:
BMJ Publishing Group
Journal:
Gut More from this journal
Pages:
gutjnl-2025
Article number:
gutjnl-2025-337030
Publication date:
2025-12-24
Acceptance date:
2025-12-02
DOI:
EISSN:
1468-3288
ISSN:
0017-5749


Language:
English
Keywords:
Pubs id:
2355286
UUID:
uuid_8ccbef06-1457-44e3-9818-56bdb553711e
Local pid:
pubs:2355286
Source identifiers:
3603391
Deposit date:
2025-12-26
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP